Treatment (other than with lenalidomide) of anemia in myelodysplastic syndrome (MDS) with del 5q (no. responders/no. treated patients).
| . | Type of MDS with del 5q . | Published Series . | GFM Experience . |
|---|---|---|---|
| Abbreviations: GFM, Groupe Francophone des Myélodysplasies; Epo, erythropoietin; G-CSF, granulocyte colony-stimulating factor; ATRA, all trans-retinoic acid | |||
| Epo or darbepoetin | 5q– syndrome | 4/8 (2 major, 2 minor) | 9/17 (9 major) |
| +/− G-CSF20 –22 | Other MDS with del 5q | 7/37 | 13/31 (6 major, 7 minor) |
| Thalidomide24 | Low-risk MDS with del 5q | Not determined | 6/20 (3 major, 3 minor) |
| ATRA25,26 | Low-risk MDS with del 5q | 12/60 (mainly minor responses) | |
| Low-dose cytarabine27 | Low-risk MDS with del 5q | 4/9 (3 major, 1 minor) | |
| Decitabine | |||
| Lubbert et al29 | Isolated del 5q and > 5% blasts | 1/1 (1 complete hematological and major cytogenetic response) | |
| Del 5q and other cytogenetic abnormalities, and > 5% blasts | 3/4 (3 complete hematological and major cytogenetic responses) | ||
| Kantarjian et al30 | High-risk MDS with del 5q | 2/16 | |
| Allogeneic bone marrow transplantation31 | Isolated del 5q Del 5q and others | 13/20 relapse-free at 1 year 8/37 relapse-free at 1 year | |
| . | Type of MDS with del 5q . | Published Series . | GFM Experience . |
|---|---|---|---|
| Abbreviations: GFM, Groupe Francophone des Myélodysplasies; Epo, erythropoietin; G-CSF, granulocyte colony-stimulating factor; ATRA, all trans-retinoic acid | |||
| Epo or darbepoetin | 5q– syndrome | 4/8 (2 major, 2 minor) | 9/17 (9 major) |
| +/− G-CSF20 –22 | Other MDS with del 5q | 7/37 | 13/31 (6 major, 7 minor) |
| Thalidomide24 | Low-risk MDS with del 5q | Not determined | 6/20 (3 major, 3 minor) |
| ATRA25,26 | Low-risk MDS with del 5q | 12/60 (mainly minor responses) | |
| Low-dose cytarabine27 | Low-risk MDS with del 5q | 4/9 (3 major, 1 minor) | |
| Decitabine | |||
| Lubbert et al29 | Isolated del 5q and > 5% blasts | 1/1 (1 complete hematological and major cytogenetic response) | |
| Del 5q and other cytogenetic abnormalities, and > 5% blasts | 3/4 (3 complete hematological and major cytogenetic responses) | ||
| Kantarjian et al30 | High-risk MDS with del 5q | 2/16 | |
| Allogeneic bone marrow transplantation31 | Isolated del 5q Del 5q and others | 13/20 relapse-free at 1 year 8/37 relapse-free at 1 year | |